表紙
市場調查報告書
商品編碼
1063709

無症狀性癌症治療的全球市場:產業分析,趨勢,市場規模,至2027年的預測

Silent Cancer Therapeutics Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2027

出版日期: | 出版商: Infinium Global Research (IGR) | 英文 100 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球無症狀性癌症治療的市場規模在預測期間內預計以10%的年複合成長率成長。

本報告提供全球無症狀性癌症治療市場調查,市場預測和概要,市場的推動因素與阻礙因素的分析,COVID-19影響,各治療法,各癌症類型,各終端用戶,各地區的市場分析,競爭情形,主要企業的簡介等系統性資訊。

目錄

第1章 序文

  • 報告的說明
  • 調查方法
  • 研究途徑

第2章 摘要整理

  • 市場概況
  • 市場預測
  • 市場地區的亮點

第3章 全球無症狀性癌症治療市場:概要

  • 簡介
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
  • COVID-19對市場的影響分析
  • 波特的五力分析
  • IGR-成長矩陣分析
    • 各治療法
    • 各癌症類型
    • 各終端用戶
    • 各地區
  • 市場價值鏈分析

第4章 無症狀性癌症治療市場:宏觀指標分析

第5章 全球無症狀性癌症治療市場:各治療法

  • 化療
  • 標靶治療
  • 放射線治療
  • 其他

第6章 全球無症狀性癌症治療市場:各癌症類型

  • 卵巢癌症
  • 前列腺癌症
  • 胰臟癌症
  • 腎癌症
  • 肝臟癌症
  • 子宮頸癌症
  • 其他

第7章 全球無症狀性癌症治療市場:各終端用戶

  • 醫院
  • 門診病人手術中心
  • 診療所
  • 其他

第8章 全球無症狀性癌症治療市場(2021年∼2027年):各地區

  • 北美
    • 各治療法
    • 各癌症類型
    • 各終端用戶
    • 各國
  • 歐洲
    • 各治療法
    • 各癌症類型
    • 各終端用戶
    • 各國
  • 亞太地區
    • 各治療法
    • 各癌症類型
    • 各終端用戶
    • 各國
  • 其他地區
    • 各治療法
    • 各癌症類型
    • 各終端用戶
    • 各子區域

第9章 企業簡介和競爭情形

  • 競爭情形
  • 企業簡介
    • Hoffmann-La Roche AG
    • AbbVie, Inc
    • Johnson & Johnson
    • Astellas Pharma, Inc
    • Novartis AG
    • Eli Lilly and Company
    • Merck KGaA
    • Bayer AG
    • GlaxoSmithKline plc
    • Salarius Pharmaceuticals
目錄
Product Code: HC08742

The report on the global silent cancer therapeutics market provides qualitative and quantitative analysis for the period from 2019 to 2027. The report predicts the global silent cancer therapeutics market to grow at a CAGR of 10% nearly the forecast period from 2021-2027. The study on silent cancer therapeutics market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2019 to 2027.

The report on silent cancer therapeutics market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global silent cancer therapeutics market over the period of 2019 to 2027. Moreover, the report is a collective presentation of primary and secondary research findings.

Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global silent cancer therapeutics market over the period of 2019 to 2027. Further, IGR- Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.

Report Findings

1) Drivers

  • The increasing number of cancer patients is expected to drive the silent cancer therapeutics market over the forecast period

2) Restraints

  • High treatment costs and the follow-up care strain both the healthcare system and patients involved in the therapy of cancers are expected to hamper the market's growth

3) Opportunities

  • With industry-standard accuracy in analysis and high data integrity, to unveil key opportunities available in the global silent cancer therapeutics market to help players in achieving a strong market position

Research Methodology

A) Primary Research

Our primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include

  • 1. Key Opinion Leaders associated with Infinium Global Research
  • 2. Internal and External subject matter experts
  • 3. Professionals and participants from the industry

Our primary research respondents typically include

  • 1. Executives working with leading companies in the market under review
  • 2. Product/brand/marketing managers
  • 3. CXO level executives
  • 4. Regional/zonal/ country managers
  • 5. Vice President level executives.

B) Secondary Research

Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. At Infinium Global Research, each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.

The secondary sources of the data typically include

  • 1. Company reports and publications
  • 2. Government/institutional publications
  • 3. Trade and associations journals
  • 4. Databases such as WTO, OECD, World Bank, and among others.
  • 5. Websites and publications by research agencies

Segment Covered

The global silent cancer therapeutics market is segmented on the basis of mode of treatment, type of cancer, and end user.

The Global Silent Cancer Therapeutics Market by Mode of Treatment

  • Chemotherapy
  • Targeted Therapy
  • Radiotherapy
  • Others

The Global Silent Cancer Therapeutics Market by Type of Cancer

  • Ovarian Cancer
  • Prostate Cancer
  • Pancreatic Cancer
  • Renal Cancer
  • Liver Cancer
  • Cervical Cancer
  • Others

The Global Silent Cancer Therapeutics Market by End User

  • Hospitals
  • Ambulatory Surgical Centres
  • Clinics
  • Others

Company Profiles

The companies covered in the report include

  • Hoffmann-La Roche AG
  • AbbVie, Inc
  • Johnson & Johnson
  • Astellas Pharma, Inc
  • Novartis AG
  • Eli Lilly and Company
  • Merck KGaA
  • Bayer AG
  • GlaxoSmithKline plc
  • Salarius Pharmaceuticals

What does this Report Deliver?

1. Comprehensive analysis of the global as well as regional markets of the silent cancer therapeutics market.

2. Complete coverage of all the segments in the silent cancer therapeutics market to analyze the trends, developments in the global market and forecast of market size up to 2027.

3. Comprehensive analysis of the companies operating in the global silent cancer therapeutics market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.

4. IGR- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.

Table of Contents

1. Preface

  • 1.1. Report Description
  • 1.2. Research Methods
  • 1.3. Research Approaches

2. Executive Summary

  • 2.1. Silent Cancer Therapeutics Market Highlights
  • 2.2. Silent Cancer Therapeutics Market Projection
  • 2.3. Silent Cancer Therapeutics Market Regional Highlights

3. Global Silent Cancer Therapeutics Market Overview

  • 3.1. Introduction
  • 3.2. Market Dynamics
    • 3.2.1. Drivers
    • 3.2.2. Restraints
    • 3.2.3. Opportunities
  • 3.3. Analysis of COVID-19 impact on the Silent Cancer Therapeutics Market
  • 3.4. Porter's Five Forces Analysis
  • 3.5. IGR-Growth Matrix Analysis
    • 3.5.1. IGR-Growth Matrix Analysis by Mode of Treatment
    • 3.5.2. IGR-Growth Matrix Analysis by Type of Cancer
    • 3.5.3. IGR-Growth Matrix Analysis by End User
    • 3.5.4. IGR-Growth Matrix Analysis by Region
  • 3.6. Value Chain Analysis of Silent Cancer Therapeutics Market

4. Silent Cancer Therapeutics Market Macro Indicator Analysis

5. Global Silent Cancer Therapeutics Market by Mode of Treatment

  • 5.1. Chemotherapy
  • 5.2. Targeted Therapy
  • 5.3. Radiotherapy
  • 5.4. Others

6. Global Silent Cancer Therapeutics Market by Type of Cancer

  • 6.1. Ovarian Cancer
  • 6.2. Prostate Cancer
  • 6.3. Pancreatic Cancer
  • 6.4. Renal Cancer
  • 6.5. Liver Cancer
  • 6.6. Cervical Cancer
  • 6.7. Others

7. Global Silent Cancer Therapeutics Market by End User

  • 7.1. Hospitals
  • 7.2. Ambulatory Surgical Centres
  • 7.3. Clinics
  • 7.4. Others

8. Global Silent Cancer Therapeutics Market by Region 2021-2027

  • 8.1. North America
    • 8.1.1. North America Silent Cancer Therapeutics Market by Mode of Treatment
    • 8.1.2. North America Silent Cancer Therapeutics Market by Type of Cancer
    • 8.1.3. North America Silent Cancer Therapeutics Market by End User
    • 8.1.4. North America Silent Cancer Therapeutics Market by Country
  • 8.2. Europe
    • 8.2.1. Europe Silent Cancer Therapeutics Market by Mode of Treatment
    • 8.2.2. Europe Silent Cancer Therapeutics Market by Type of Cancer
    • 8.2.3. Europe Silent Cancer Therapeutics Market by End User
    • 8.2.4. Europe Silent Cancer Therapeutics Market by Country
  • 8.3. Asia-Pacific
    • 8.3.1. Asia-Pacific Silent Cancer Therapeutics Market by Mode of Treatment
    • 8.3.2. Asia-Pacific Silent Cancer Therapeutics Market by Type of Cancer
    • 8.3.3. Asia-Pacific Silent Cancer Therapeutics Market by End User
    • 8.3.4. Asia-Pacific Silent Cancer Therapeutics Market by Country
  • 8.4. RoW
    • 8.4.1. RoW Silent Cancer Therapeutics Market by Mode of Treatment
    • 8.4.2. RoW Silent Cancer Therapeutics Market by Type of Cancer
    • 8.4.3. RoW Silent Cancer Therapeutics Market by End User
    • 8.4.4. RoW Silent Cancer Therapeutics Market by Sub-region

9. Company Profiles and Competitive Landscape

  • 9.1. Competitive Landscape in the Global Silent Cancer Therapeutics Market
  • 9.2. Companies Profiles
    • 9.2.1. Hoffmann-La Roche AG
    • 9.2.2. AbbVie, Inc
    • 9.2.3. Johnson & Johnson
    • 9.2.4. Astellas Pharma, Inc
    • 9.2.5. Novartis AG
    • 9.2.6. Eli Lilly and Company
    • 9.2.7. Merck KGaA
    • 9.2.8. Bayer AG
    • 9.2.9. GlaxoSmithKline plc
    • 9.2.10. Salarius Pharmaceuticals